Russia may face shortage of anti-AIDS drugs in 2015
Russia may face with a shortage of anti-AIDS drugs in 2015 due to the current complex situation in the national economy and devaluation of the rouble, according to recent statements of Vadim Pokrovsky, head of the Russian Federal Research and Methodological Center for Prevention and Control of AIDS.
According to Mr Pokrovsky, at present there are about 700,000 HIV-infected people in the country of which about 350,000 should regularly receive therapy.
The Pharma Letter’s Russia correspondent reports that the number of HIV-infected patients in Russia is steadily growing. In 2013 about 80,000 new cases were registered. The figures for 2014 have not yet been announced but, according to people at the Russian Ministry of Health, they will be significantly higher the figures of 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze